The total purchase price to ALTANA AG is expected to amount to approx. EUR4.5 billion. This amount consists of a debt-free/cash-free valuation of ALTANA Pharma AG of EUR4.215 billion and an additional amount of approx. EUR0.3 billion after price adjustment at closing (net cash/working capital).
Divested of its pharmaceutical arm, Altana AG will focus on its specialty chemicals business ALTANA Chemie. The completion of the transaction is subject to antitrust clearances in the EU and the U.S, and approval of the sharaholders of ALTANA AG in December 2006.
The deal is expected to close by the end of the year and the transfer of the business is planned as of Jan 1, 2007.
Further details of the acquisition are discussed in Altana's and Nycomed's press releases.
Comment Preview